Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sanja Sever
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Trisaq, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Sever is a co-founder of Trisaq, a company developing drugs and devices to modulate molecular targets that have a pivotal role in the plasticity of podocyte foot processes and has licensed IP related to targeting dynamin oligomerization in kidney diseases. The research
tests whether a dynamin mutant that has the propensity to oligomerize and is expected to promote microtubule depolymerization can counteract podocyte injury by using microtubule drugs that either promote or inhibit microtubule polymerization. The company could therefore have an interest in the results of the research. Based on the magnitude of Dr. Sever’s financial interest in Trisaq and the close connection between the company’s interests and the research, the Partners Committee on Outside Activities (COA) review panel determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Dynamin, actin and microtubules: cytoskeletal crosstalk in podocytes
Project Narrative Under this grant application we propose to study the role of the regulatory GTPase dynamin in regulating crosstalk between the actin cytoskeleton and microtubules in podocytes. While podocytes are terminally differentiated cells, some forms of glomerular injury such as HIV-associated nephropathy result in podocyte de- differentiation and cell proliferation, a process driven by crosstalk between actin and microtubules. Under this grant application we study the role of dynamin as a link between microtubules and the actin cytoskeleton in podocytes in health and diseases.
Filed on May 30, 2018.
Tell us what you know about Sanja Sever's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Sanja Sever filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Sanja Sever | Massachusetts General Hospital | Conflict of Interest | Trisaq, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.